Cargando…
Acute oesophageal safety and long-term follow-up of AI-guided high-power short-duration with 50 W for atrial fibrillation ablation
AIMS: Pulmonary vein isolation using radiofrequency ablation is an effective treatment option for patients with symptomatic atrial fibrillation (AF). Application of high power over a short period of time (HPSD) is reported to create more efficient lesions and may prevent collateral thermal oesophage...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105862/ https://www.ncbi.nlm.nih.gov/pubmed/36881791 http://dx.doi.org/10.1093/europace/euad053 |
_version_ | 1785026301586833408 |
---|---|
author | Müller, Julian Nentwich, Karin Berkovitz, Artur Ene, Elena Sonne, Kai Zhuravlev, Vitaly Chakarov, Ivaylo Barth, Sebastian Waechter, Christian Behnes, Michael Halbfass, Philipp Deneke, Thomas |
author_facet | Müller, Julian Nentwich, Karin Berkovitz, Artur Ene, Elena Sonne, Kai Zhuravlev, Vitaly Chakarov, Ivaylo Barth, Sebastian Waechter, Christian Behnes, Michael Halbfass, Philipp Deneke, Thomas |
author_sort | Müller, Julian |
collection | PubMed |
description | AIMS: Pulmonary vein isolation using radiofrequency ablation is an effective treatment option for patients with symptomatic atrial fibrillation (AF). Application of high power over a short period of time (HPSD) is reported to create more efficient lesions and may prevent collateral thermal oesophageal injury. This study aims to compare efficacy and safety of two different HPSD ablation approaches using different ablation index settings. METHODS AND RESULTS: Consecutive patients undergoing AF ablation with HPSD (50 W; ablation index–guided) using the ThermoCool SmartTouch SF catheter were included. Patients were grouped by ablation protocol: ablation with target ablation index (AI) of 400 on the anterior left atrial wall vs. 300 at the posterior left atrial wall (AI 400/300) or AI 450/350 was performed upon the operator’s preference and compared. Peri-procedural parameters and complications were recorded, and incidences of endoscopically detected thermal oesophageal lesions (EDEL) analysed. Recurrence rates after a mean follow-up of 25 ± 7 months and reconnection patterns in patients undergoing redo procedures were investigated. A total of 795 patients (67 ± 10 years; 58% male; 48% paroxysmal AF) underwent a first AF ablation with HPSD (211 in group AI 400/300 and 584 in group 450/350). Median procedure time was 82.9 ± 24.6 min with longer ablation times in patients with target AI 400/300 due to higher intraprocedural reconnection rates, increased box lesions, and additional right atrial isthmus ablations. EDEL rates among target AI 400/300 procedures were significantly lower (3% vs. 7%; P = 0.019). Correspondingly, AI 450/350 was the strongest independent predictor of post-ablation EDEL (OR 4.799, CI 1.427–16.138, P = 0.011). Twelve-month (76% vs. 76%; P = 0.892) and long-term ablation single procedure success (68% vs. 71%; log-rank P = 0.452) after a mean of 25 ± 7 months were comparable among both target AI groups; however, long-term success was significantly higher for paroxysmal AF compared to persistent AF (12 months: 80% vs. 72%; P = 0.010; end of follow-up: 76% vs. 65%; log-rank P = 0.001). One hundred three patients (16%) underwent a redo procedure during follow-up documented comparable pulmonary vein (PV) reconnection among groups. Multivariate predictors of AF recurrence were age, left atrium (LA) size, persistent AF, and extra-PV ablation targets. CONCLUSION: High-power short-duration AF ablation with target AI of 400 for non-posterior wall and 300 for posterior wall lesions resulted in comparable long-term results compared to higher AI (450/350) ablations with significantly lower risk for thermal oesophageal lesions. Older age, larger LA size, persistent AF, and extra-PV ablation targets were identified in a multivariate analysis as independent risk factors for recurrences of atrial arrhythmias. |
format | Online Article Text |
id | pubmed-10105862 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-101058622023-04-17 Acute oesophageal safety and long-term follow-up of AI-guided high-power short-duration with 50 W for atrial fibrillation ablation Müller, Julian Nentwich, Karin Berkovitz, Artur Ene, Elena Sonne, Kai Zhuravlev, Vitaly Chakarov, Ivaylo Barth, Sebastian Waechter, Christian Behnes, Michael Halbfass, Philipp Deneke, Thomas Europace Clinical Research AIMS: Pulmonary vein isolation using radiofrequency ablation is an effective treatment option for patients with symptomatic atrial fibrillation (AF). Application of high power over a short period of time (HPSD) is reported to create more efficient lesions and may prevent collateral thermal oesophageal injury. This study aims to compare efficacy and safety of two different HPSD ablation approaches using different ablation index settings. METHODS AND RESULTS: Consecutive patients undergoing AF ablation with HPSD (50 W; ablation index–guided) using the ThermoCool SmartTouch SF catheter were included. Patients were grouped by ablation protocol: ablation with target ablation index (AI) of 400 on the anterior left atrial wall vs. 300 at the posterior left atrial wall (AI 400/300) or AI 450/350 was performed upon the operator’s preference and compared. Peri-procedural parameters and complications were recorded, and incidences of endoscopically detected thermal oesophageal lesions (EDEL) analysed. Recurrence rates after a mean follow-up of 25 ± 7 months and reconnection patterns in patients undergoing redo procedures were investigated. A total of 795 patients (67 ± 10 years; 58% male; 48% paroxysmal AF) underwent a first AF ablation with HPSD (211 in group AI 400/300 and 584 in group 450/350). Median procedure time was 82.9 ± 24.6 min with longer ablation times in patients with target AI 400/300 due to higher intraprocedural reconnection rates, increased box lesions, and additional right atrial isthmus ablations. EDEL rates among target AI 400/300 procedures were significantly lower (3% vs. 7%; P = 0.019). Correspondingly, AI 450/350 was the strongest independent predictor of post-ablation EDEL (OR 4.799, CI 1.427–16.138, P = 0.011). Twelve-month (76% vs. 76%; P = 0.892) and long-term ablation single procedure success (68% vs. 71%; log-rank P = 0.452) after a mean of 25 ± 7 months were comparable among both target AI groups; however, long-term success was significantly higher for paroxysmal AF compared to persistent AF (12 months: 80% vs. 72%; P = 0.010; end of follow-up: 76% vs. 65%; log-rank P = 0.001). One hundred three patients (16%) underwent a redo procedure during follow-up documented comparable pulmonary vein (PV) reconnection among groups. Multivariate predictors of AF recurrence were age, left atrium (LA) size, persistent AF, and extra-PV ablation targets. CONCLUSION: High-power short-duration AF ablation with target AI of 400 for non-posterior wall and 300 for posterior wall lesions resulted in comparable long-term results compared to higher AI (450/350) ablations with significantly lower risk for thermal oesophageal lesions. Older age, larger LA size, persistent AF, and extra-PV ablation targets were identified in a multivariate analysis as independent risk factors for recurrences of atrial arrhythmias. Oxford University Press 2023-03-07 /pmc/articles/PMC10105862/ /pubmed/36881791 http://dx.doi.org/10.1093/europace/euad053 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Clinical Research Müller, Julian Nentwich, Karin Berkovitz, Artur Ene, Elena Sonne, Kai Zhuravlev, Vitaly Chakarov, Ivaylo Barth, Sebastian Waechter, Christian Behnes, Michael Halbfass, Philipp Deneke, Thomas Acute oesophageal safety and long-term follow-up of AI-guided high-power short-duration with 50 W for atrial fibrillation ablation |
title | Acute oesophageal safety and long-term follow-up of AI-guided high-power short-duration with 50 W for atrial fibrillation ablation |
title_full | Acute oesophageal safety and long-term follow-up of AI-guided high-power short-duration with 50 W for atrial fibrillation ablation |
title_fullStr | Acute oesophageal safety and long-term follow-up of AI-guided high-power short-duration with 50 W for atrial fibrillation ablation |
title_full_unstemmed | Acute oesophageal safety and long-term follow-up of AI-guided high-power short-duration with 50 W for atrial fibrillation ablation |
title_short | Acute oesophageal safety and long-term follow-up of AI-guided high-power short-duration with 50 W for atrial fibrillation ablation |
title_sort | acute oesophageal safety and long-term follow-up of ai-guided high-power short-duration with 50 w for atrial fibrillation ablation |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105862/ https://www.ncbi.nlm.nih.gov/pubmed/36881791 http://dx.doi.org/10.1093/europace/euad053 |
work_keys_str_mv | AT mullerjulian acuteoesophagealsafetyandlongtermfollowupofaiguidedhighpowershortdurationwith50wforatrialfibrillationablation AT nentwichkarin acuteoesophagealsafetyandlongtermfollowupofaiguidedhighpowershortdurationwith50wforatrialfibrillationablation AT berkovitzartur acuteoesophagealsafetyandlongtermfollowupofaiguidedhighpowershortdurationwith50wforatrialfibrillationablation AT eneelena acuteoesophagealsafetyandlongtermfollowupofaiguidedhighpowershortdurationwith50wforatrialfibrillationablation AT sonnekai acuteoesophagealsafetyandlongtermfollowupofaiguidedhighpowershortdurationwith50wforatrialfibrillationablation AT zhuravlevvitaly acuteoesophagealsafetyandlongtermfollowupofaiguidedhighpowershortdurationwith50wforatrialfibrillationablation AT chakarovivaylo acuteoesophagealsafetyandlongtermfollowupofaiguidedhighpowershortdurationwith50wforatrialfibrillationablation AT barthsebastian acuteoesophagealsafetyandlongtermfollowupofaiguidedhighpowershortdurationwith50wforatrialfibrillationablation AT waechterchristian acuteoesophagealsafetyandlongtermfollowupofaiguidedhighpowershortdurationwith50wforatrialfibrillationablation AT behnesmichael acuteoesophagealsafetyandlongtermfollowupofaiguidedhighpowershortdurationwith50wforatrialfibrillationablation AT halbfassphilipp acuteoesophagealsafetyandlongtermfollowupofaiguidedhighpowershortdurationwith50wforatrialfibrillationablation AT denekethomas acuteoesophagealsafetyandlongtermfollowupofaiguidedhighpowershortdurationwith50wforatrialfibrillationablation |